🔬CBDV (CBDV)

What is CBDV?

CBDV, short for cannabidivarin, is a naturally occurring, non-intoxicating cannabinoid found in the cannabis plant. If CBD is the well-known headliner, CBDV is its quieter close relative: nearly the same molecule, made by the same plant along nearly the same chemical route, but usually present in far smaller amounts and only recently pulled into the scientific spotlight.

What makes it interesting is what got trimmed. CBDV belongs to a small club of cannabinoids nicknamed the 'varins,' each one carrying a shorter carbon tail than its more famous cousin. That tiny structural edit is enough to give CBDV a character of its own, and it is a big part of why researchers have spent the past decade taking a much closer look at a compound that sat mostly ignored for decades.

Commonly associated effects

CBDV is commonly associated with the following qualities. These reflect general research and community reports, not guaranteed or medical outcomes.

CBD with a shorter tail

Line up CBDV next to CBD and they look almost identical, because they nearly are. The one meaningful difference is a small chain of carbon atoms hanging off the molecule. CBD carries a five-carbon (pentyl) tail; CBDV carries a three-carbon (propyl) one, as if two links were snipped off. That trimmed tail is exactly what the '-varin' suffix signals, and CBDV shares it with a small family of cannabinoids including THCV, CBGV, and CBCV. Chemically it lands at the formula C19H26O2 (a molecular weight of roughly 286 g/mol). Like CBD, it is non-intoxicating: it does not switch on the CB1 receptor the way THC does, so it is not the part of cannabis that makes people feel high.

How the plant makes it, and why scientists are curious

CBDV is built inside the sticky glandular trichomes on female cannabis flowers. The plant follows the same assembly line it uses for CBD, but starts from a slightly shorter building block (divarinolic acid), which routes through a varin-family precursor and, with a little heat and age, becomes CBDV. It was first isolated back in 1969, yet its pharmacology only drew serious attention decades later, after rodent studies reported anticonvulsant activity that appeared not to run through the usual CB1 pathway. Those findings pushed CBDV into early human trials for epilepsy. Research is still exploring what it may or may not do, so it is best thought of as a compound scientists are actively studying rather than a settled remedy.

Frequently asked questions

Other cannabinoids